|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 188.80 SEK | -1.97% |
|
-4.84% | -5.36% |
| 17/06 | Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta | FW |
| 13/06 | BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review | MT |
| Capitalization | 1.67TCr 172.76Cr 149.85Cr 141.15Cr 128.25Cr 237.27Cr 15TCr 267.34Cr 639.67Cr 6.85TCr 648.23Cr 634.43Cr 25TCr | P/E ratio 2025 * |
15.8x | P/E ratio 2026 * | 50.7x |
|---|---|---|---|---|---|
| Enterprise value | 1.51TCr 156.56Cr 135.8Cr 127.92Cr 116.23Cr 215.02Cr 14TCr 242.27Cr 579.68Cr 6.21TCr 587.45Cr 574.94Cr 23TCr | EV / Sales 2025 * |
7.95x | EV / Sales 2026 * | 12.2x |
| Free-Float |
44.08% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: BioArctic AB
More recommendations
More press releases
More news
| 1 day | -1.97% | ||
| 1 week | -4.84% | ||
| Current month | +3.79% | ||
| 1 month | +4.60% | ||
| 3 months | -10.10% | ||
| 6 months | -11.28% | ||
| Current year | -5.36% |
| 1 week | 186 |  | 201.8 |
| 1 month | 172.9 | | 205.8 |
| Current year | 154.4 | | 271.4 |
| 1 year | 137.7 | | 271.4 |
| 3 years | 74.5 | | 392 |
| 5 years | 66.7 | | 392 |
| 10 years | 20.4 | | 392 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 01/01/2013 | |
| Director of Finance/CFO | 54 | 01/06/2023 | |
Johanna Fälting
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/01/2012 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 24/01/2003 | |
| Chairman | 76 | 28/01/2003 | |
Eugen Steiner
CHM | Chairman | 71 | 01/06/2023 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 1.25% | 4 M€ | +17.62% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.97% | -4.84% | -12.59% | +150.73% | 172.76Cr | ||
| +0.39% | -1.51% | +17.39% | +13.79% | 4.84TCr | ||
| -2.25% | -8.36% | +58.27% | +58.71% | 2.93TCr | ||
| +0.08% | -1.38% | -28.45% | -23.30% | 2.68TCr | ||
| +1.25% | +0.87% | +0.01% | +18.08% | 2.62TCr | ||
| -40.00% | +142.71% | +35,996.87% | +4,341.46% | 1.88TCr | ||
| +0.10% | -1.36% | +12.82% | -18.94% | 1.23TCr | ||
| -1.14% | -4.17% | +138.51% | - | 1.18TCr | ||
| +2.02% | +0.56% | -54.05% | -28.87% | 1.16TCr | ||
| +3.63% | +3.57% | +38.37% | +106.35% | 1.07TCr | ||
| Average | -3.79% | +12.40% | +3,616.71% | +513.11% | 1.98TCr | |
| Weighted average by Cap. | -3.63% | +11.64% | +3,439.84% | +455.59% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 190.56Cr 20Cr 17Cr 16Cr 15Cr 27Cr 1.71TCr 30Cr 73Cr 781.45Cr 74Cr 72Cr 2.87TCr | 122.43Cr 13Cr 11Cr 10Cr 9.39Cr 17Cr 1.1TCr 20Cr 47Cr 502.08Cr 47Cr 46Cr 1.85TCr |
| Net income | 103.62Cr 11Cr 9.29Cr 8.75Cr 7.95Cr 15Cr 927.59Cr 17Cr 40Cr 424.94Cr 40Cr 39Cr 1.56TCr | 33Cr 3.39Cr 2.94Cr 2.77Cr 2.52Cr 4.66Cr 293.94Cr 5.25Cr 13Cr 134.66Cr 13Cr 12Cr 494.99Cr |
| Net Debt | -156.74Cr -16Cr -14Cr -13Cr -12Cr -22Cr -1.4TCr -25Cr -60Cr -642.77Cr -61Cr -59Cr -2.36TCr | -177.26Cr -18Cr -16Cr -15Cr -14Cr -25Cr -1.59TCr -28Cr -68Cr -726.91Cr -69Cr -67Cr -2.67TCr |
More financial data
* Estimated data
Employees
116
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/25/19 | 188.80 kr | -1.97% | 7,40,340 |
| 18/25/18 | 192.60 kr | -2.28% | 2,51,275 |
| 17/25/17 | 197.10 kr | -1.20% | 1,47,344 |
| 16/25/16 | 199.50 kr | +0.55% | 1,72,686 |
Delayed Quote Nasdaq Stockholm, June 19, 2025 at 09:30 pm IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
188.80SEK
Average target price
289.40SEK
Spread / Average Target
+53.28%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIOA B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition